Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.37 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.37 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8467365 | 0.88 | CYP1A2 (0.58) | CYP1A2CYP2D6MAPK1 | |
| Methyl Alcohol SCHEMBL8169228 | 0.73 | CYP1A2 (0.61) | CYP1A2CYP2D6MAPK1YTHDC1 | |
| SCHEMBL8165731 | 0.73 | AHCY (0.48) | CYP1A2CYP2D6MAPK1ADORA1 | |
| SCHEMBL8158053 | 0.73 | CYP1A2 (0.64) | CYP1A2CYP2D6MAPK1YTHDC1 | |
| SCHEMBL8850005 | 0.71 | CYP1A2 (0.50) | CYP1A2CYP2D6MAPK1ADORA1 | |
| SCHEMBL18410857 | 0.71 | MAPK1 (0.57) | CYP1A2CYP2D6MAPK1ADORA1 | |
| SCHEMBL10172072 | 0.70 | ADORA2A (0.58) | ADORA1 | |
| SCHEMBL10172070 | 0.70 | ADORA2A (0.58) | ADORA1 | |
| SCHEMBL10172012 | 0.70 | ADORA2A (0.58) | ADORA1 | |
| SCHEMBL8168971 | 0.66 | CYP1A2 (0.33) | CYP1A2CYP2D6MAPK1ADORA1YTHDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6110923-A | Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity | BIOCHEM PHARMA INC. (CA) | 2000-08-29 | — | — | US | claimed |
| US-6110923-A | Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity | BIOCHEM PHARMA INC. (CA) | 2000-08-29 | — | — | US | disclosed |
| US-5994361-A | ANTITUMOR, ANTICANCER AGENT | BIOCHEM PHARMA (CA) | 1999-11-30 | — | — | US | disclosed |
| EP-0766683-A1 | NOVEL SUBSTITUTED PURINYL DERIVATIVES WITH IMMUNOMODULATING ACTIVITY | BIOCHEM PHARMA INC (CA) | 1997-04-09 | — | — | EP | disclosed |
| WO-1995035297-A1 | NOVEL SUBSTITUTED PURINYL DERIVATIVES WITH IMMUNOMODULATING ACTIVITY | BIOCHEM PHARMA INC. (CA) | 1995-12-28 | — | — | WO | disclosed |